You are here


  • ESMO Guidelines

    Introduction by Stefan Zimmermann

    The ESMO Clinical Practice Guidelines, prepared and reviewed by leading experts, will help you provide your patients with the best care options. Evidence-based medicine transfers the results of cancer research into new standards and methods for clinical practice. Thanks to ESMO’s regularly updated Clinical Practice Guidelines, the decisions you make every day are supported by the informed consensus of the leading experts in our profession.

    The following guidelines encompass early-stage NSCLC, locally advanced disease, and advanced disease, and cover epidemiology, diagnosis, staging, treatment, and follow-up and survivorship. Beyond their readability, these sets of guidelines will help you make practical decisions: you will find detailed levels and grades of recommendation, standardised algorithms or flow charts, and Magnitude of Clinical benefit Scale scores.


  • ESMO Pocket Guidelines Mobile App

    Don’t forget to download the ESMO Interactive Guidelines App on your smartphone (available for both iPhone and Android), and the ESMO Cancer Guides Library App, where you will find the handy pocket guidelines for thoracic tumours! 

  • NCCN Guidelines

    Introduction by Tom Stinchcombe

    The National Comprehensive Cancer Network (NCCN) consists of 27 cancer centers in the United States who work collaboratively to develop guidelines for treatment by disease site, supportive care, and detection, prevention, and risk reduction for all cancers. The thoracic oncology panels include members from medical oncology, thoracic surgery, pathology, and patient advocates. The panels update the guidelines regularly and then develop convenient flow diagrams for each clinical situation, with supportive text and references at the end of the guidelines. In the United States, the NCCN guidelines are used to assess quality of care, and can be used to support coverage from third-party payers. The NCCN qualifies recommendations, and the higher levels of evidence and/or consensus are category 1 and category 2A. Category 2B represents a lower level of evidence and/or agreement and category 3 indicates there is disagreement about the role of the intervention. All recommendations are 2A unless otherwise noted. In thoracic oncology, guidelines are available for non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, thymoma and thymic carcinomas, lung cancer screening, and smoking cessation.  Guidelines are available for providers as well as patients. The guidelines are readily available at:



    TNM Staging